Table 2.
Plasma proteins in MI day 3 plasma that predict survival and day 7 dilation and tracked with day 3 dilation
| Zero-Order Correlation Coefficient (r) | β | SE | P Value | Adjusted R2 | |
|---|---|---|---|---|---|
| MI survival | |||||
| A2M | −0.70* | −6.81 × 10−8 | 3.22 × 10−8 | 0.034 | Pseudo R2 0.66 |
| EAF1 | −0.65* | −1.12 × 10−8 | 5.70 × 10−9 | 0.049 | |
| D3 diastolic volume | |||||
| APOBEC2 | −0.60* | −2.23 × 10−7 | 4.88 × 10−8 | <0.001 | 0.67 |
| RanBP2 | −0.49* | 4.76 × 10−9 | 1.62 × 10−9 | 0.011 | |
| FMNL2 | −0.58* | −4.60 × 10−8 | 1.57 × 10−8 | 0.011 | |
| CD40L | −0.44* | 5.94 × 10−8 | 2.07 × 10−8 | 0.012 | |
| ASB17 | −0.46* | −2.14 × 10−7 | 8.46 × 10−8 | 0.024 | |
| Vmn2r106 | 0.49* | 1.23 × 10−7 | 6.73 × 10−8 | 0.089 | |
| D7 diastolic volume | |||||
| NUDCD3 | −0.48* | −2.37 × 10−6 | 5.19 × 10−7 | <0.001 | 0.56 |
| KIF3C | −0.47* | 7.18 × 10−8 | 1.95 × 10−8 | 0.0016 | |
| FMNL2 | −0.51* | −1.04 × 10−7 | 2.85 × 10−8 | 0.0017 | |
| ATP6V0D1 | −0.51* | 1.22 × 10−6 | 4.11 × 10−7 | 0.0080 | |
| C7 | −0.43* | −2.21 × 10−7 | 7.52 × 10−8 | 0.0084 | |
| MYO1A | −0.52* | −8.02 × 10−7 | 3.22 × 10−7 | 0.022 | |
| UBIAD1 | −0.39* | −1.29 × 10−7 | 5.45 × 10−8 | 0.029 | |
| CEP131 | −0.48* | 5.47 × 10−8 | 3.13 × 10−8 | 0.096 | |
Proteins that best predict MI survival and dilation were selected using automatic model selection. Proteins are ranked by P value. *P < 0.05 for the zero-order correlation coefficient. A2M, α2-macroglobulin; ASB17, ankyrin repeat and SOCS box protein 17; APOBEC2, C->U editing enzyme APOBEC 2; ATP6V0D1, V type proton ATPase subunit d; C7, complement component C7; CD40L, CD40 ligand; CEP131, centrosomal protein of 131 kDa; D3, day 3; D7, day 7; EAF1, ELL-associated factor 1; FMNL2, formin-like protein 2; KIF3C, kinesin-like protein KIF3C; MYO1A, unconventional myosin Ia; NUDCD3, nudC-domain-containing protein 3; RanBP2, E3 SUMO-protein ligase RanBP2; UBIAD1, ubiA prenyltransferase domain-containing protein 1; VMN2R106, vomeronasal receptor Vmn2r106.